Compound that can inhibit UBC13-UEV interactions, pharmaceutical compositions and therapeutic uses

The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1;...

Full description

Saved in:
Bibliographic Details
Main Authors OKATSU TIMOTHY THOMSON, PEYPOCH ANGEL MESSEGUER, ORTIZ ANGEL RAMIREZ, MASIP ISABEL MASIP, SIGMUND JOHANNA SCHEPER, RUIZ DOMINGO GONZALEZ, MELGUIZO, LEGAL REPRESENTATIVE MARIA LUZ ORTIZ, DE LEON ANTONIO MORREALE, DE ROZAS GLORIA SANCLIMENS PEREZ, CLAVERIA, LEGAL REPRESENTATIVE MA CARMEN FABREGA, FERNANDEZ ALEJANDRA MOURE
Format Patent
LanguageEnglish
Published 28.08.2012
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
Online AccessGet full text

Cover

More Information
Summary:The invention relates to a compound (I) wherein R is a heterocyclyl radical; R1 and R2 are independently H or alkyl; R3 is H, alkyl, cycloalkyl, cycloalkylalkyl, alkenyl, aryl, arylalkyl, heterocyclyl or heterocyclylalkyl; R4 and R5 are independently H or alkyl; q is a number selected from 0 and 1; and the salts, solvates, prodrugs or stereoisomers thereof having inhibitory activity for UBC13-UEV interactions and which can be used in the production of pharmaceutical compositions intended for antitumor therapy or the treatment and/or prophylaxis of diseases associated to metabolic pathways involving the UBC13 enzyme, metabolic pathways involving transcriptional factor NF- B, or pathways involving PCNA or RAD6. R-(CR1R2)q-CO-N(R3)-C(R4R5)-CO-NH2  (I)
Bibliography:Application Number: US20070309429